Results 101 to 110 of about 999,584 (309)

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Nuclear medicine [PDF]

Postgraduate Medical Journal, 1992
openaire   +5 more sources

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Nuclear medicine in the management of patients with heart failure

, 2014
Amalia Peix, Cláudio Tinoco Mesquita, Diana Páez, Carlos Cunha Pereira, R Felix, Claudia Gutiérrez, Rodrigo Jaimovich, Bárbara Maria Ianni, José Soares, Pastor Olaya, Ma. Victoria Rodriguez, Albert Flotats, Raffaele Giubbini, Mark I. Travin, Ernest Garcia   +14 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Essential nuclear medicine physics

Indian Journal of Radiology and Imaging, 2007
N. C. Purandare, V. Rangarajan
doaj   +1 more source

Clinical Nuclear Medicine [PDF]

, 2008
E. Edmund Kim
openalex   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Nuclear Medicine in Finland

World Journal of Nuclear Medicine, 2012
Kalevi Kairemo
doaj   +1 more source

Clinical Guideline for Precision Nuclear Medicine Diagnosis and Treatment of Neuroendocrine Neoplasms (2025 Edition)

Xiehe Yixue Zazhi
In Western developed countries, precision nuclear medicine diagnosis and treatment for neuroendocrine neoplasms (NENs) have been widely adopted in clinical practice.
Chinese Society of Nuclear Medicine in Chinese Medical Association, Chinese Neuroendocrine Tumor Society in China International Exchange and Promotive Association for Medical and Health Care   +1 more
doaj   +1 more source